Tirzepatide is a first-of-its-kind dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This dual mechanism allows it to powerfully mimic two key incretin hormones. Research demonstrates its exceptional efficacy in supporting glycemic control, improving insulin sensitivity, and promoting significant weight loss through reduced appetite and caloric intake. It is regarded as a major advancement in peptide therapeutics for metabolic health.